Any current/future new fundraising through debt or equity?

No plans to raise equity to repay debt as per Harshil Dalal. Interest rates (LIBOR/SOFR) are expected to decrease, reducing interest costs, making debt cheaper than equity. The company will continue managing hedging actively to handle foreign currency exposure. Focus is on generating free cash flow to reduce net debt over the next 2-2.5 years, targeting a net debt-to-EBITDA ratio below 2 by FY '27. No mention of new debt fundraising; emphasis is on maintaining and reducing current debt levels through cash flow rather than new borrowings.

Any current/future capex/capital investment/strategic investment?

Major capex related to growth has largely been completed; future capex will mainly be maintenance-focused. Total capex in the first half of the financial year was about INR125 crores; expected full-year capex around INR250 crores, including digital transformation activities. Discussions underway for a potential 2-digit million investment in a specific facility to debottleneck supply chain capacity, linked to a customer project ramp-up in the second half. Continued investment in digitalization and operational excellence to improve efficiency and profitability. No plans presently to rais

Future growth expectations in sales/revenue/volumes?

Bavla site in India expects 25% to 30% growth in the next financial year, aiming to normalize operations and improve margins (Page 17). Overall company revenue growth estimated around 8% to 9% for the full fiscal year (Page 9). Carbogen Amcis targeting CHF 255 million revenue for FY '25 and is on track to achieve this (Page 8). CRAMS Carbogen Amcis business saw a commercial revenue growth of about 52% compared to last year Q2 (Page 6). Increase in inquiries and order books expected post-election, leading to new project capture in early 2025 (Pages 8, 9). French facility expected to reach break

Future growth expectations in earnings/operating earnings/profits/EPS?

Revenue growth expected at 8-9% for the full year FY '25; previous outlook mentioned 5-10%. EBITDA margin forecast to improve to at least 16% for FY '25, with aspirations to reach 25% steady-state margin in 2-3 years post normalization of operations. Long-term target EBITDA margin around 25%-30%, driven by French facility breaking even, India operations normalizing (historically >30% EBITDA margin), and reduced raw material costs in the Netherlands. Net debt to EBITDA ratio targeted to reduce to less than 2 (1.5 to 2 range) by FY '27, supported by free cash flow and EBITDA growth. Earn

Current/ Expected Orderbook/ Pending Orders?

Carbogen Amcis order book decreased from CHF 142 million to CHF 110 million as of September 30, 2024. The decrease is considered transient, mainly due to market slowdown and election-related wait in the U.S. The product commercial pipeline remains stable. There is cautious optimism with new orders expected in the second half of the year and early 2025. A new contract with a German customer for over CHF 1 million was recently secured. Total orders in hand for the new French facility exceed CHF 10 million. The market is expected to pick up post-U.S. presidential election with increased venture c

Dishman CarbogenQ2 FY25Pharmaceuticals & Biotechnology

Dishman Carbogen Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹150P/E: 145.4Market Cap: ₹2.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

Order

Capex

Yes

2 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 3

Bavla site in India expects 25% to 30% growth in the next financial year, aiming to normalize operations and improve margins (Page 17).
Overall company revenue growth estimated around 8% to 9% for the full fiscal year (Page 9).
Carbogen Amcis targeting CHF 255 million revenue for FY '25 and is on track to achieve this (Page 8).
CRAMS Carbogen Amcis business saw a commercial revenue growth of about 52% compared to last year Q2 (Page 6).
Increase in inquiries and order books expected post-election, leading to new project capture in early 2025 (Pages 8, 9).
French facility expected to reach break-even in the next financial year with revenue growth from €9.5 million in H1 to €18-19 million next year (Page 9).
Long term goal to reach steady-state EBITDA margin of ~25-30% supported by improved operations in India, France, and reduction in raw material prices in Netherlands (Page 17).

Margin guidance

Category 1

Revenue growth expected at 8-9% for the full year FY '25; previous outlook mentioned 5-10%.
EBITDA margin forecast to improve to at least 16% for FY '25, with aspirations to reach 25% steady-state margin in 2-3 years post normalization of operations.
Long-term target EBITDA margin around 25%-30%, driven by French facility breaking even, India operations normalizing (historically >30% EBITDA margin), and reduced raw material costs in the Netherlands.
Net debt to EBITDA ratio targeted to reduce to less than 2 (1.5 to 2 range) by FY '27, supported by free cash flow and EBITDA growth.
Earnings expected to improve with operating efficiencies, new contracts, especially in Carbogen Amcis and India business.
French facility anticipated to break even EBITDA by FY '26 with revenues of €18-19 million.
PAT margin in Q2 FY '25 was about 4.2%, with a profit-before-tax increase of INR42 crores, signaling improving profitability.

See what Dishman Carbogen management said on margin guidance — free account, 30 seconds.

Fundraise plans

No plans to raise equity to repay debt as per Harshil Dalal.
Interest rates (LIBOR/SOFR) are expected to decrease, reducing interest costs, making debt cheaper than equity.
The company will continue managing hedging actively to handle foreign currency exposure.
Focus is on generating free cash flow to reduce net debt over the next 2-2.5 years, targeting a net debt-to-EBITDA ratio below 2 by FY '27.
No mention of new debt fundraising; emphasis is on maintaining and reducing current debt levels through cash flow rather than new borrowings.

Order book

Carbogen Amcis order book decreased from CHF 142 million to CHF 110 million as of September 30, 2024.
The decrease is considered transient, mainly due to market slowdown and election-related wait in the U.S.
The product commercial pipeline remains stable.
There is cautious optimism with new orders expected in the second half of the year and early 2025.
A new contract with a German customer for over CHF 1 million was recently secured.
Total orders in hand for the new French facility exceed CHF 10 million.
The market is expected to pick up post-U.S. presidential election with increased venture capital activity.
Increased orders from existing customers observed, particularly in mid to large molecules manufacturing shifting from China.
The Bavla site in India is expected to ramp up orders with 25%-30% growth anticipated next financial year.

See what Dishman Carbogen management said on order book — free account, 30 seconds.

Capex plans

Yes

Major capex related to growth has largely been completed; future capex will mainly be maintenance-focused.
Total capex in the first half of the financial year was about INR125 crores; expected full-year capex around INR250 crores, including digital transformation activities.
Discussions underway for a potential 2-digit million investment in a specific facility to debottleneck supply chain capacity, linked to a customer project ramp-up in the second half.
Continued investment in digitalization and operational excellence to improve efficiency and profitability.
No plans presently to raise equity for debt repayment; interest rates expected to decrease, reducing finance costs.

Track Dishman Carbogen — get its next earnings analysis in your feed

How does Dishman Carbogen rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisDishman Carbogen

Rev 3Mar 1

See where Dishman Carbogen sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Dishman Carbogen rank in Pharmaceuticals & Biotechnology?

Compare Dishman Carbogen against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Dishman Carbogen's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →